All In MedTech

Device Trial Radar · NCT05438017

Performance Evaluation of the Dreem 3 System for Sleep Assessment in Patients With Insomnia

Assessment of the Performance of the Dreem 3 System for EEG Sleep Monitoring in the Lab Setting

Last checked: Nov 20, 2026Latest source record: Jul 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

41

Actual

Start

Apr 21, 2022

Primary completion

Jul 8, 2022

Study completion Jul 8, 2022

Sponsor

Lead sponsor
DreemNot on our public-company list
Sponsor type
Industry
First posted
Jun 29, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated device
Yes
Who can join
All sexes, from 22 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of the clinical investigation is to assess the performance of the Dreem 3 System for sleep assessment compared to a FDA-cleared PSG assessment and human sleep expert scoring in a population experiencing insomnia symptoms.

Conditions

  • Insomnia

Interventions

  • Dreem 3 System vs PSGDevice

    Dreem 3 System to be worn by each participant while undergoing in-lab sleep study with PSG.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Performance of the automatic sleep stage scoring of the Dreem 3 System compared to the consensus of 3 independent certified sleep scorers realized on the polysomnography signal.Time frame: Day 1

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Biotrial Inc

    Newark, New Jersey

  • Biotrial Rennes

    Rennes, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.